文献速递脊柱关节炎

古塞奇尤单抗在银屑病关节炎各疾病领域提供持久改善:一项3期随机双盲安慰剂对照研究的事后分析

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.
PubMed 文献 · RMD Open · 2024-03-26

该事后分析基于DISCOVER-2研究,纳入未使用过生物制剂或Janus激酶抑制剂的活動性银屑病关节炎患者,随机接受古塞奇尤单抗每4周或每8周或安慰剂。至第100周,古塞奇尤单抗在多个GRAPPA认可领域显示早期且持久的改善,相当比例患者达到重要治疗目标。

要点

  • 古塞奇尤单抗每4周/每8周组至第100周在肿胀/压痛关节、银屑病、脊柱疼痛、附着点炎/指趾炎方面均显示持久改善。
  • 第100周时,每4周/每8周组分别有62%/59%达到疾病活动指数低疾病活动度,61%/70%附着点炎缓解,72%/83%指趾炎缓解。
  • 至第112周,古塞奇尤单抗随机组未发生炎症性肠病病例,报告1例葡萄膜炎。

核心结论

  • 在未使用过生物制剂的活動性银屑病关节炎患者中,古塞奇尤单抗在GRAPPA认可的关键领域提供早期且持久的改善,持续至2年,相当比例患者达到重要治疗目标。

研究设计与样本

  • DISCOVER-2(NCT03158285)是一项3期随机双盲安慰剂对照研究,本分析为事后分析。
  • 纳入未使用过生物制剂或Janus激酶抑制剂的活動性银屑病关节炎患者(≥5个肿胀关节/≥5个压痛关节,C反应蛋白≥0.6 mg/dL),按1:1:1随机分配至古塞奇尤单抗每4周、每8周或安慰剂(后交叉至古塞奇尤单抗)。
  • 共493例随机分配至古塞奇尤单抗的患者中442例(90%)完成至第100周的治疗。

主要发现

  • 古塞奇尤单抗治疗后疾病活动度早期下降,随后在关键银屑病关节炎领域(肿胀/压痛关节、银屑病、脊柱疼痛、附着点炎/指趾炎)观察到持久改善,持续至第100周。
  • 古塞奇尤单抗每4周/每8周组至第100周的治疗相关目标应答率普遍增加:银屑病关节炎疾病活动指数低疾病活动度62%/59%,附着点炎缓解61%/70%,指趾炎缓解72%/83%,银屑病面积和严重程度指数100%改善59%/53%,银屑病关节炎疾病活动评分低疾病活动度51%/49%,最低疾病活动度38%/40%。
  • 至第112周,古塞奇尤单抗随机组未发生炎症性肠病病例,报告1例葡萄膜炎。

关键数值与推荐

  • 银屑病关节炎疾病活动指数低疾病活动度:古塞奇尤单抗每4周组62%,每8周组59%。
  • 附着点炎缓解:每4周组61%,每8周组70%。
  • 指趾炎缓解:每4周组72%,每8周组83%。
  • 银屑病面积和严重程度指数100%改善:每4周组59%,每8周组53%。
  • 银屑病关节炎疾病活动评分低疾病活动度:每4周组51%,每8周组49%;最低疾病活动度:每4周组38%,每8周组40%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 指甲银屑病未评估。
  • 银屑病关节炎相关疾病(炎症性肠病/葡萄膜炎)通过不良事件评估至第112周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluate long-term guselkumab effectiveness across Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-recognised domains/related conditions of psoriatic arthritis (PsA). METHODS: Post hoc analyses used data from DISCOVER-2 (NCT03158285) biologic/Janus-kinase inhibitor-naïve participants with active PsA (≥5 swollen/≥5 tender joints, C-reactive protein ≥0.6 mg/dL), randomised (1:1:1) to guselkumab every 4 or 8 weeks (Q4W/Q8W) or placebo with crossover to guselkumab. Outcomes aligned with key GRAPPA-recognised domains of overall disease activity, peripheral arthritis, axial disease, enthesitis/dactylitis and skin psoriasis (nail psoriasis was not evaluated). PsA-related conditions (inflammatory bowel disease (IBD)/uveitis) were assessed via adverse events through W112. Least squares mean changes from baseline through W100 in continuous outcomes employed repeated measures mixed-effects models adjusting for baseline scores. Binary measure response rates were determined with non-responder imputation for missing data. RESULTS: 442/493 (90%) of guselkumab-randomised patients completed treatment through W100. Following early reductions in disease activity with guselkumab, durable improvements were observed across key PsA domains (swollen/tender joints, psoriasis, spinal pain, enthesitis/dactylitis) through W100. Response rates of therapeutically relevant targets generally increased through W100 with guselkumab Q4W/Q8W: Disease Activity Index for PsA low disease activity (LDA) 62%/59%, enthesitis resolution 61%/70%, dactylitis resolution 72%/83%, 100% improvement in Psoriasis Area and Severity Index 59%/53%, Psoriatic Arthritis Disease Activity Score LDA 51%/49% and minimal disease activity 38%/40%. Through W112, no cases of IBD developed among guselkumab-randomised patients and one case of uveitis was reported. CONCLUSION: In biologic-naïve patients with active PsA, guselkumab provided early and durable improvements in key GRAPPA-recognised domains through 2 years, with substantial proportions achieving important treatment targets.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Coates LC, Gossec L, Zimmermann M, et al. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study. RMD Open. 2024. PMID: 38531621. doi:10.1136/rmdopen-2023-003977

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。